Innovent Biologics (1801N) Stock Forecast & Price Target
1801N Analyst Ratings
Strong Buy
18Buy0Hold0Sell
Based on 18 analysts giving stock ratings to Innovent Biologics in the past 3 months
1801N Stock 12 Month Forecast
Average Price Target
MXN 324.62▲(0.00% Upside)Based on 18 Wall Street analysts offering 12 month price targets for Innovent Biologics in the last 3 months. The average price target is MXN 324.62 with a high forecast of MXN 359.71 and a low forecast of MXN 283.26. The average price target represents a ― change from the last price of ―.
Highest Price TargetHighestMXN 359.71Average Price TargetMXN 324.62Lowest Price TargetLowestMXN 283.26
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
 Unknown AnalystNot Ranked | Huatai Securities | MXN 310.17 | buy | ― | Reiterated | 10/31/26 | ||
| Jill Wu | CMB International Securities | MXN 331.94 | buy | ― | Reiterated | 10/27/26 | ||
| Unknown AnalystNot Ranked | UBS | MXN 323.96 | buy | ― | Reiterated | 10/19/26 | ||
| Unknown AnalystNot Ranked | Bernstein | MXN 306.48 | buy | ― | Reiterated | 09/22/26 | ||
| Unknown AnalystNot Ranked | Citic Securities | MXN 299.30 | buy | ― | Reiterated | 09/17/26 | ||
| Mark Kong CFA | DBS | MXN 344.79 | buy | ― | Reiterated | 09/15/26 | ||
| Unknown AnalystNot Ranked | BOCOM International Holdings Company | MXN 282.54→MXN 308.88 | buy | ― | Reiterated | 09/02/26 | ||
| Unknown AnalystNot Ranked | CSC Financial | MXN 353.65→MXN 355.19 | buy | ― | Reiterated | 08/28/26 | ||
| Unknown AnalystNot Ranked | Citi | MXN 275.36→MXN 358.20 | buy | ― | Reiterated | 08/27/26 | ||
| Unknown AnalystNot Ranked | Jefferies | MXN 299.30 | buy | ― | Reiterated | 08/27/26 | ||
| Yang Huang | J.P. Morgan | MXN 280.15→MXN 335.22 | buy | ― | Reiterated | 08/27/26 | ||
| Unknown AnalystNot Ranked | CICC | MXN 283.26 | buy | ― | Reiterated | 08/26/26 | ||
| Unknown AnalystNot Ranked | CLSA | MXN 334.98→MXN 349.82 | buy | ― | Reiterated | 08/26/26 | ||
| Unknown AnalystNot Ranked | Daiwa | MXN 287.33→MXN 323.24 | buy | ― | Reiterated | 08/26/26 | ||
| Unknown AnalystNot Ranked | Bank of America Securities | MXN 335.22 | buy | ― | Reiterated | 08/26/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Unknown AnalystNot Ranked | 10/31/26 | MXN 310.17 | buy | ― | Reiterated | Huatai Securities | ||
| Jill Wu | 10/27/26 | MXN 331.94 | buy | ― | Reiterated | CMB International Securities | ||
| Unknown AnalystNot Ranked | 10/19/26 | MXN 323.96 | buy | ― | Reiterated | UBS | ||
| Unknown AnalystNot Ranked | 09/22/26 | MXN 306.48 | buy | ― | Reiterated | Bernstein | ||
| Unknown AnalystNot Ranked | 09/17/26 | MXN 299.30 | buy | ― | Reiterated | Citic Securities | ||
| Mark Kong CFA | 09/15/26 | MXN 344.79 | buy | ― | Reiterated | DBS | ||
| Unknown AnalystNot Ranked | 09/02/26 | MXN 282.54→MXN 308.88 | buy | ― | Reiterated | BOCOM International Holdings Company | ||
| Unknown AnalystNot Ranked | 08/28/26 | MXN 353.65→MXN 355.19 | buy | ― | Reiterated | CSC Financial | ||
| Unknown AnalystNot Ranked | 08/27/26 | MXN 275.36→MXN 358.20 | buy | ― | Reiterated | Citi | ||
| Unknown AnalystNot Ranked | 08/27/26 | MXN 299.30 | buy | ― | Reiterated | Jefferies | ||
| Yang Huang | 08/27/26 | MXN 280.15→MXN 335.22 | buy | ― | Reiterated | J.P. Morgan | ||
| Unknown AnalystNot Ranked | 08/26/26 | MXN 283.26 | buy | ― | Reiterated | CICC | ||
| Unknown AnalystNot Ranked | 08/26/26 | MXN 334.98→MXN 349.82 | buy | ― | Reiterated | CLSA | ||
| Unknown AnalystNot Ranked | 08/26/26 | MXN 287.33→MXN 323.24 | buy | ― | Reiterated | Daiwa | ||
| Unknown AnalystNot Ranked | 08/26/26 | MXN 335.22 | buy | ― | Reiterated | Bank of America Securities |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Innovent Biologics
3 Months
Success Rate8/15 ratings generated profit
53%
Average Return
+8.16%
Copying Jill Wu's trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +8.16% per trade.
1 Year
Success Rate10/15 ratings generated profit
67%
Average Return
+37.97%
Copying Jill Wu's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +37.97% per trade.
2 Years
Success Rate8/12 ratings generated profit
67%
Average Return
+55.27%
Copying Rebecca Liang's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +55.27% per trade.
1801N Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 11 | 6 | 2 | 2 | 2 |
| Buy | 8 | 24 | 27 | 25 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 19 | 30 | 29 | 27 | 10 |
In the current month, 1801N has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1801N average Analyst price target in the past 3 months is 324.62.
1801N Financial Forecast
HighMXN 3.11
ConsensusMXN 3.11
LowMXN 3.11
1801N Earnings Forecast
Next quarter’s earnings estimate for 1801N is MXN 3.11 with a range of MXN 3.11 to MXN 3.11. The previous quarter’s EPS was MXN 1.96. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 30.8B
ConsensusMXN 29.8B
LowMXN 28.9B
1801N Sales Forecast
Next quarter’s sales forecast for 1801N is MXN 29.82B with a range of MXN 28.86B to MXN 30.78B. The previous quarter’s sales results were MXN 23.37B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
1801N Stock Forecast FAQ
What is MX:1801N’s average 12-month price target, according to analysts?
Based on analyst ratings, Innovent Biologics’s 12-month average price target is Mex$324.62.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Innovent Biologics a Buy, Sell or Hold?
Innovent Biologics has a consensus rating of Strong Buy, which is based on 18 buy ratings, 0 hold ratings and 0 sell ratings.
What is Innovent Biologics’s share price target?
The average share price target for Innovent Biologics is Mex$324.62. This is based on 18 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$359.71, and the lowest forecast is Mex$283.26. The average share price target represents a 0.00% increase from the current price of ―.
What do analysts say about Innovent Biologics?
Innovent Biologics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Street analysts.
How can I buy shares of Innovent Biologics?
To buy shares of MX:1801N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
